Header Logo

Connection

Jeffrey Swanson to Schizophrenia

Back to Details
This is a "connection" page, showing publications Jeffrey Swanson has written about Schizophrenia.
Jeffrey Swanson
Connection Strength
3.058
Schizophrenia
  1. Swanson JW. Alternative Perspectives on Police Encounters and Psychotic Experiences [Invited Commentary on DeVylder et al, "Psychotic Experiences in the Context of Police Victimization"]. Schizophr Bull. 2017 09 01; 43(5):946-948.
    View in: PubMed
    Score: 0.459
  2. Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry. 2008 Jul; 193(1):37-43.
    View in: PubMed
    Score: 0.243
  3. Swanson JW, Van Dorn RA, Swartz MS, Smith A, Elbogen EB, Monahan J. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum Behav. 2008 Jun; 32(3):228-40.
    View in: PubMed
    Score: 0.227
  4. Swanson J, Van Dorn RA, Swartz MS. Effectiveness of atypical antipsychotics for substance use in schizophrenia patients. Schizophr Res. 2007 Aug; 94(1-3):114-8.
    View in: PubMed
    Score: 0.226
  5. Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry. 2006 May; 63(5):490-9.
    View in: PubMed
    Score: 0.209
  6. Ringeisen H, Edlund M, Guyer H, Dever J, Carpenter L, Olfson M, First M, Geiger P, Liao D, Peytchev A, Carr C, Chwastiak L, Dixon LB, Monroe-Devita M, Scott Stroup T, Swanson J, Swartz M, Gibbons R, Stambaugh L, Bareis N, Smith TE, Kessler RC. Prevalence of Past-Year Mental and Substance Use Disorders, 2021-2022. Psychiatr Serv. 2025 Aug 01; 76(8):720-728.
    View in: PubMed
    Score: 0.196
  7. Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry. 2004 Dec; 65(12):1666-73.
    View in: PubMed
    Score: 0.190
  8. Bareis N, Edlund M, Ringeisen H, Guyer H, Dixon LB, Olfson M, Smith TE, Chwastiak L, Monroe-DeVita M, Swartz M, Swanson J, Sinclair Hancq E, Geiger P, Kreski NT, Stroup TS. Characterizing Schizophrenia Spectrum Disorders: Results of the U.S. Mental and Substance Use Disorders Prevalence Study. Psychiatr Serv. 2025 Jan 01; 76(1):2-12.
    View in: PubMed
    Score: 0.187
  9. Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull. 2004; 30(1):3-20.
    View in: PubMed
    Score: 0.178
  10. Swanson JW. On Thoughts, Threats, and Throwing the Spear. Schizophr Bull. 2016 07; 42(4):883-4.
    View in: PubMed
    Score: 0.104
  11. Robertson AG, Swanson JW, Lin H, Easter MM, Frisman LK, Swartz MS. Influence of Criminal Justice Involvement and Psychiatric Diagnoses on Treatment Costs Among Adults With Serious Mental Illness. Psychiatr Serv. 2015 Sep; 66(9):907-9.
    View in: PubMed
    Score: 0.098
  12. Robertson AG, Swanson JW, Frisman LK, Lin H, Swartz MS. Patterns of justice involvement among adults with schizophrenia and bipolar disorder: key risk factors. Psychiatr Serv. 2014 Jul; 65(7):931-8.
    View in: PubMed
    Score: 0.092
  13. Van Dorn RA, Swanson JW, Swartz MS, Elbogen E, Ferron J. Reducing barriers to completing psychiatric advance directives. Adm Policy Ment Health. 2008 Nov; 35(6):440-8.
    View in: PubMed
    Score: 0.061
  14. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res. 2008 Mar; 100(1-3):39-52.
    View in: PubMed
    Score: 0.059
  15. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller DD, Reimherr F, Khan A, Ca?ive JM, Lieberman JA. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv. 2006 Aug; 57(8):1110-6.
    View in: PubMed
    Score: 0.053
  16. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis. 2006 Mar; 194(3):164-72.
    View in: PubMed
    Score: 0.052
  17. Slade EP, Salkever DS, Rosenheck R, Swanson J, Swartz M, Shern D, Gallucci G, Harding C, Palmer L, Russo P, Hough RL, Barrio C, Garcia P. Cost-sharing requirements and access to mental health care among medicare enrollees with schizophrenia. Psychiatr Serv. 2005 Aug; 56(8):960-6.
    View in: PubMed
    Score: 0.050
  18. Van Dorn RA, Swanson JW, Swartz MS, Elbogen EB. The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia. Ment Health Serv Res. 2005 Jun; 7(2):123-34.
    View in: PubMed
    Score: 0.049
  19. Van Dorn RA, Swanson JW, Elbogen EB, Swartz MS. A comparison of stigmatizing attitudes toward persons with schizophrenia in four stakeholder groups: perceived likelihood of violence and desire for social distance. Psychiatry. 2005; 68(2):152-63.
    View in: PubMed
    Score: 0.048
  20. Swartz MS, Wagner HR, Swanson JW, Elbogen EB. Consumers' perceptions of the fairness and effectiveness of mandated community treatment and related pressures. Psychiatr Serv. 2004 Jul; 55(7):780-5.
    View in: PubMed
    Score: 0.046
  21. Swartz MS, Swanson JW, Hannon MJ. Detection of illicit substance use among persons with schizophrenia by radioimmunoassay of hair. Psychiatr Serv. 2003 Jun; 54(6):891-5.
    View in: PubMed
    Score: 0.043
  22. Swartz MS, Swanson JW, Wagner HR, Hannon MJ, Burns BJ, Shumway M. Assessment of four stakeholder groups' preferences concerning outpatient commitment for persons with schizophrenia. Am J Psychiatry. 2003 Jun; 160(6):1139-46.
    View in: PubMed
    Score: 0.043
  23. Swartz MS, Swanson JW, Hannon MJ. Does fear of coercion keep people away from mental health treatment? Evidence from a survey of persons with schizophrenia and mental health professionals. Behav Sci Law. 2003; 21(4):459-72.
    View in: PubMed
    Score: 0.042
  24. Buchanan A, Sint K, Swanson J, Rosenheck R. Correlates of Future Violence in People Being Treated for Schizophrenia. Am J Psychiatry. 2019 09 01; 176(9):694-701.
    View in: PubMed
    Score: 0.032
  25. Robertson AG, Easter MM, Lin H, Frisman LK, Swanson JW, Swartz MS. Medication-Assisted Treatment for Alcohol-Dependent Adults With Serious Mental Illness and Criminal Justice Involvement: Effects on Treatment Utilization and Outcomes. Am J Psychiatry. 2018 07 01; 175(7):665-673.
    View in: PubMed
    Score: 0.030
  26. Robertson AG, Swanson JW, Van Dorn RA, Swartz MS. Treatment participation and medication adherence: effects on criminal justice costs of persons with mental illness. Psychiatr Serv. 2014 Oct; 65(10):1189-91.
    View in: PubMed
    Score: 0.023
  27. Wilder CM, Elbogen EB, Moser LL, Swanson JW, Swartz MS. Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. Psychiatr Serv. 2010 Apr; 61(4):380-5.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.